GAMMA Investing LLC Has $142,000 Holdings in Alkermes plc $ALKS

GAMMA Investing LLC lessened its stake in Alkermes plc (NASDAQ:ALKS) by 8.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,963 shares of the company’s stock after selling 433 shares during the quarter. GAMMA Investing LLC’s holdings in Alkermes were worth $142,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Twin Tree Management LP acquired a new stake in shares of Alkermes in the 1st quarter valued at approximately $29,000. Brooklyn Investment Group lifted its holdings in Alkermes by 1,071.1% during the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock valued at $35,000 after purchasing an additional 964 shares during the last quarter. Quantbot Technologies LP lifted its holdings in Alkermes by 54.5% during the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after purchasing an additional 385 shares during the last quarter. USA Financial Formulas acquired a new stake in Alkermes during the 1st quarter valued at $49,000. Finally, Fifth Third Bancorp lifted its holdings in Alkermes by 54.4% during the 1st quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock valued at $49,000 after purchasing an additional 521 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Up 4.1%

Alkermes stock opened at $29.04 on Tuesday. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.45. The business’s 50-day moving average price is $27.89 and its two-hundred day moving average price is $29.33. The stock has a market cap of $4.79 billion, a PE ratio of 13.96, a P/E/G ratio of 1.57 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last released its earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.The firm had revenue of $390.66 million for the quarter, compared to analysts’ expectations of $343.20 million. During the same quarter in the previous year, the business posted $1.16 earnings per share. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. As a group, analysts expect that Alkermes plc will post 1.31 earnings per share for the current year.

Analyst Ratings Changes

ALKS has been the subject of several research reports. JPMorgan Chase & Co. raised their price target on Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, September 9th. UBS Group raised Alkermes from a “neutral” rating to a “buy” rating and raised their price target for the company from $33.00 to $42.00 in a report on Tuesday, June 17th. Needham & Company LLC set a $43.00 price target on Alkermes in a report on Tuesday, September 9th. The Goldman Sachs Group assumed coverage on Alkermes in a report on Tuesday, July 15th. They set a “buy” rating and a $43.00 target price for the company. Finally, HC Wainwright reissued a “neutral” rating and set a $46.00 target price on shares of Alkermes in a report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Alkermes has a consensus rating of “Buy” and an average price target of $42.00.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.